Summary & Overview

CPT 0050U: MyAML™ NGS Panel for Acute Myelogenous Leukemia

CPT code 0050U identifies the MyAML™ NGS Panel, a proprietary next‑generation sequencing (NGS) assay that targets 194 genes to detect sequence and copy number variants associated with acute myelogenous leukemia (AML). As a PLA code, 0050U maps to a single manufacturer‑specific test and signals molecular precision diagnostics increasingly used in hematologic oncology for diagnosis, prognostication, and therapeutic decision support. Nationally, PLA codes like 0050U matter because they enable distinct tracking and payer policy development for proprietary assays that lack generic CPT descriptors.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and service setting, information on common billing modifiers, and where to expect policy variation across commercial and public payers. The publication summarizes benchmarks and coverage themes relevant to proprietary NGS panels, highlights implications for laboratory billing workflows, and outlines typical sites of service and clinical uses within AML care pathways. Data not available in the input are noted where applicable, including specific payer policies, allowable amounts, and utilization benchmarks.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0050UCPTPLAnext-generation sequencingNGS panelmolecular diagnosticsacute myelogenous leukemialaboratory

Billing Code Overview

CPT code 0050U is a Proprietary Laboratory Analyses (PLA) code assigned to the MyAML™ NGS Panel by LabPMM LLC, an Invivoscribe Technologies, Inc., Company. The test is a next‑generation targeted sequencing (NGS) assay that analyzes 194 genes to detect sequence and copy number variants associated with acute myelogenous leukemia (AML).

Service type: Laboratory-based molecular diagnostic sequencing (next‑generation sequencing targeted panel)

Typical site of service: Clinical laboratory or specialized molecular diagnostics laboratory; specimen collection typically occurs in ambulatory clinics, hospitals, or outpatient phlebotomy centers.

Clinical & Coding Specifications

Clinical Context

A 62-year-old patient with newly diagnosed acute myelogenous leukemia (AML) presents to a hematology/oncology clinic after abnormal peripheral blood counts and a confirmatory bone marrow biopsy. The treating hematologist orders the MyAML™ NGS Panel (0050U) by LabPMM LLC to identify sequence and copy number variants across 194 genes associated with AML. A peripheral blood or bone marrow aspirate specimen is collected in appropriate EDTA or preservative tubes and sent to the performing laboratory. The laboratory performs next-generation targeted sequencing and bioinformatic analysis, reports pathogenic and likely pathogenic variants, and provides a clinical report to the ordering provider to guide prognosis, targeted therapy selection, and eligibility for clinical trials. Typical workflow steps include specimen collection, requisition and test ordering by the hematologist, courier transport to the reference laboratory, laboratory processing and sequencing, result validation by laboratory personnel, and result delivery to the ordering provider. Common sites of service are hospital inpatient settings, outpatient hematology/oncology clinics, and independent reference laboratories.

Coding Specifications

Modifier	Description	When to Use
`00`	Default/No modifier	General reporting when no specific modifier applies.

11 | Professional Component | When reporting the professional interpretation component separately (rare for PLA tests; used if local lab only provides interpretation).

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Ordering providers who manage AML diagnosis and direct molecular testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C92.0`	Acute myeloblastic leukemia, not having achieved remission	Primary AML diagnosis often prompting comprehensive NGS panel testing to identify actionable mutations.

C92.00 | Acute myeloblastic leukemia not having achieved remission, without maturation | Specific AML subtype frequently evaluated with mutation profiling for prognosis and therapy.

C92.01 | Acute myeloblastic leukemia not having achieved remission, with maturation | Subclassification of AML where molecular profiling informs risk stratification.

C92.10 | Acute myelomonocytic leukemia, not having achieved remission | AML variant where targeted sequencing assists therapeutic decisions.

D47.Z2 | Other chronic myeloproliferative disease, unspecified | Disorders with potential progression to AML where NGS may be used to assess transformation risk.

Z51.11 | Encounter for antineoplastic chemotherapy | Patients undergoing or planning chemotherapy often require molecular profiling to guide regimen selection.

R76.8 | Other specified abnormal immunological findings | Abnormal laboratory findings prompting further molecular diagnostic evaluation in hematologic disease.

OpenPayer